TLR4 and melanoma: We have previously provided evidence of the significance of monocyte TLR4 expression in the TRIMEL-mediated ex vivo functional differentiation of TAPCells and the impact of a TLR4 hypofunctional single-nucleotide polymorphism (Asp299Gly; rs4986790) on the clinical efficacy of TAPCells in melanoma patients [19].